Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance

How 1 sources are covering this

• CNBCLean R·1d ago

  Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance

  Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

  Read at CNBC →